These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 5677210)

  • 21. Clinical evaluation of the effect of glyclopyramide in diabetes mellitus.
    Yamagata S; Goto Y; Oneda A; Kikuchi J; Toyota T
    Tohoku J Exp Med; 1969 Jun; 98(2):155-69. PubMed ID: 5811101
    [No Abstract]   [Full Text] [Related]  

  • 22. ORAL HYPOGLYCEMIC DRUGS: COMPARATIVE EVALUATION OF TOLBUTAMIDE, CHLORPROPAMIDE AND PHENFORMIN.
    MOSS JM; DELAWTER DE; GALLAGHER EJ
    Med Times; 1964 Jul; 92():645-54. PubMed ID: 14184191
    [No Abstract]   [Full Text] [Related]  

  • 23. [Blood sugar, serum insulin, nonesterified fatty acids and somatotropin in daily profile in adult diabetics under monotherapy with various sulfonylureas].
    Happ J; Beyer J; Nest E; Fröhlich A; Althoff PH; Schöffling K
    Arzneimittelforschung; 1974 Aug; 24(8):1228-34. PubMed ID: 4214173
    [No Abstract]   [Full Text] [Related]  

  • 24. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
    Tattersall RB
    Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of control of blood glucose on plasma insulin responses to various stimuli in secondary failures to oral hypoglycemic agents and in newly diagnosed, maturity onset, ketosis-resistant diabetics.
    Schmeltz R; Wendorff HJ; Field JB
    J Clin Endocrinol Metab; 1978 Apr; 46(4):519-27. PubMed ID: 755038
    [No Abstract]   [Full Text] [Related]  

  • 26. Insulin response to glucose in the presence of oral hypoglycemics.
    Arky RA; Abramson EA
    Ann N Y Acad Sci; 1968 Mar; 148(3):768-77. PubMed ID: 5241475
    [No Abstract]   [Full Text] [Related]  

  • 27. Circadian variation of glucose, insulin and free fatty acids during the long-term use of oral hypoglycaemic agents in diabetes mellitus with special reference to glibenclamide.
    Hadden DR; Bhatia SK; Rigas A; Weaver JA; Montgomery DA
    Postgrad Med J; 1970 Dec; ():Suppl:53-7. PubMed ID: 5533298
    [No Abstract]   [Full Text] [Related]  

  • 28. [THE THERAPY OF DIABETES MELLITUS].
    CAGLI V
    Policlinico Prat; 1964 Jan; 71():1-21. PubMed ID: 14126452
    [No Abstract]   [Full Text] [Related]  

  • 29. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE; Calderara A; Pacchioni M; Cassisa C; Pozza G
    Diabete Metab; 1993; 19(1):30-5. PubMed ID: 8504882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma insulin and glucose levels in maturity onset diabetics treated with chlorpropamide.
    Shenfield GM; Logan A; Shirling D; Baird J
    Diabetologia; 1977 Aug; 13(4):367-71. PubMed ID: 913926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Insulin liberation by blood sugar decreasing sulfonamides and by glucose in adult diabetic patients].
    Haupt E; Köberich W; Rosak C; Beyer J; Schöffling K
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2198. PubMed ID: 4198967
    [No Abstract]   [Full Text] [Related]  

  • 33. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
    Kudzma DJ; Friedberg SJ
    Diabetes; 1977 Apr; 26(4):291-5. PubMed ID: 321288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral management of uncomplicated maturity onset diabetes.
    Mashaly M; el-Ebrashy N; Higazi AM; Einen MA; Aziz MT
    J Egypt Med Assoc; 1974; 57(7-8):288-97. PubMed ID: 4217809
    [No Abstract]   [Full Text] [Related]  

  • 35. [On the clinical use of biguanides].
    Haese E
    Arzneimittelforschung; 1969 Apr; 19(4):633-8. PubMed ID: 5819164
    [No Abstract]   [Full Text] [Related]  

  • 36. [Influence of therapy on glucose and lipid metabolism as well as insulin secretion in diabetes mellitus].
    Lohmann D; Verlohren HJ; Pohl A; Brückner U
    Dtsch Z Verdau Stoffwechselkr; 1976; 36(2):77-84. PubMed ID: 1017406
    [No Abstract]   [Full Text] [Related]  

  • 37. [Serum immunoreactive insulin after the oral administration of single dose of tolbutamide. I. Peripheral vein immunoreactive insulin in normal subjects and mild diabetics (author's transl)].
    Goto A
    Nihon Naibunpi Gakkai Zasshi; 1975 Aug; 51(8):676-84. PubMed ID: 1237421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of diabetes mellitus with oral hypoglycaemic drugs.
    Duncan LJ; Clarke BF; Munro JF
    Curr Med Drugs; 1965 Jun; 5(10):23-32. PubMed ID: 5878054
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of long-term tolbutamide treatment on glucose tolerance and insulin secretion in maturity-onset diabetes without obesity.
    Lauvaux JP; Mandart G; Heymans G; Ooms HA
    Horm Metab Res; 1972 Mar; 4(2):58-62. PubMed ID: 5028221
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.